Albemarle (NYSE:ALB) Given New $92.00 Price Target at Robert W. Baird

Albemarle (NYSE:ALB) had its target price lowered by Robert W. Baird from $103.00 to $92.00 in a report released on Wednesday morning. Robert W. Baird currently has a neutral rating on the specialty chemicals company’s stock.

ALB has been the topic of a number of other research reports. Evercore ISI cut shares of Albemarle from an “outperform” rating to an “inline” rating in a research report on Wednesday, February 5th. KeyCorp decreased their target price on shares of Albemarle from $132.00 to $127.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 12th. BMO Capital Markets decreased their target price on shares of Albemarle from $150.00 to $140.00 in a research report on Wednesday. Clarkson Capital began coverage on shares of Albemarle in a research report on Tuesday, January 14th. They issued a “buy” rating and a $112.00 target price on the stock. Finally, Oppenheimer decreased their target price on shares of Albemarle from $171.00 to $170.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $114.24.

Albemarle Trading Up 1.1 %

NYSE:ALB opened at $76.57 on Wednesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.58 and a current ratio of 2.44. The firm has a market cap of $9.00 billion, a price-to-earnings ratio of -4.57, a price-to-earnings-growth ratio of 3.43 and a beta of 1.59. Albemarle has a 52 week low of $71.97 and a 52 week high of $143.19. The firm has a 50-day moving average price of $90.00 and a two-hundred day moving average price of $92.48.

Albemarle (NYSE:ALB) last posted its quarterly earnings data on Wednesday, February 12th. The specialty chemicals company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.49). Albemarle had a negative net margin of 28.80% and a positive return on equity of 1.67%. On average, equities analysts expect that Albemarle will post -1.55 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO J Kent Masters sold 2,525 shares of Albemarle stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $101.12, for a total transaction of $255,328.00. Following the sale, the chief executive officer now owns 73,747 shares of the company’s stock, valued at approximately $7,457,296.64. The trade was a 3.31 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.38% of the company’s stock.

Institutional Investors Weigh In On Albemarle

A number of large investors have recently modified their holdings of the stock. Quarry LP boosted its stake in Albemarle by 1,400.0% during the third quarter. Quarry LP now owns 270 shares of the specialty chemicals company’s stock worth $26,000 after acquiring an additional 252 shares in the last quarter. Assetmark Inc. boosted its stake in Albemarle by 340.6% during the fourth quarter. Assetmark Inc. now owns 304 shares of the specialty chemicals company’s stock worth $26,000 after acquiring an additional 235 shares in the last quarter. Trust Co. of Vermont boosted its stake in Albemarle by 606.5% during the fourth quarter. Trust Co. of Vermont now owns 325 shares of the specialty chemicals company’s stock worth $28,000 after acquiring an additional 279 shares in the last quarter. Eastern Bank bought a new stake in Albemarle during the third quarter worth about $31,000. Finally, Cromwell Holdings LLC boosted its stake in Albemarle by 61.9% during the third quarter. Cromwell Holdings LLC now owns 387 shares of the specialty chemicals company’s stock worth $37,000 after acquiring an additional 148 shares in the last quarter. Institutional investors own 92.87% of the company’s stock.

Albemarle Company Profile

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services.